Drugs / FLT190
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04455230 | Sep 2020 → Sep 2023 | Fabry disease | Spur Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT04040049 | Jul 2019 → May 2023 | Fabry disease | Spur Therapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLT190 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04040049 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “FLT190 is a recombinant adeno- associated viral (AAV) vector.” NCT04040049 ↗ |
| Route | Intravenous | “On Day 0, FLT190 will be administered as a single dose, slow intravenous infusion.” NCT04040049 ↗ |
| Target | GLA | “FLT190 consists of a potent, synthetic capsid (AAVS3) containing an expression cassette with a codon-optimized human GLA cDNA under the control of a liver-specific promoter...” PMID 36631545 ↗ Jan 2023 |